NetworkNewsBreaks Archive - Page 1926 of 2081

WednesdayOct 18, 2017 9:30 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Approaching Commercialization of IGC-AD1 in Early 2018

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, the expression of GSK3β is reduced by as much as 62 percent. “Based on this and other previously announced compelling data, we are readying IGC-AD1, brand name Hyalolex, in a liquid formulation for commercialization in early 2018,” Ram Mukunda, CEO of IGC, stated in the news release. “We have identified Germany, Canada and certain licensed medical…

TuesdayOct 17, 2017 12:33 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on October 17, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: NEOT 100.13% – News: Enters merger agreement with Evofem Biosciences, Inc. to create women's health company INSG 9.56% – News: Moves on momentum from recent collaboration deal AMDA 5.60% – News: Receives listing extension from Nasdaq BLSP 4.74% – News: Posts shareholder update DRNE 4.17% – News: Secures contract with U.S. Department of Defense for WASP system MYSZ 3.88% – News: Adds Susan Moses and supermodel Emme to team ASRV 3.85% – News: Posts…

TuesdayOct 17, 2017 12:29 pm

NetworkNewsBreaks – Diffusion Pharmaceuticals, Inc. (NASDAQ: DFFN) Shares Surge after Receiving Final FDA Protocol Guidance for TSC Phase 3 Clinical Trial

Shares of Diffusion Pharmaceuticals, Inc. (NASDAQ: DFFN) are up 35.4% this morning after the company said it has received final protocol guidance from the U.S. Food and Drug Administration (FDA) for a phase 3 clinical trial with trans sodium crocetinate (TSC) in patients newly diagnosed with inoperable glioblastoma multiforme (GBM), a type of brain cancer. The trial will compare survival at two years of patients receiving the company’s lead compound TSC with chemotherapy and radiation (standard of care), with patients receiving the standard of care alone. Diffusion intends to begin the trial under the protocol agreed upon by the FDA…

TuesdayOct 17, 2017 12:08 pm

NetworkNewsBreaks – PotNetwork Holding, Inc. (POTN) Subsidiary on Pace for Record-Breaking Quarter

PotNetwork Holding, Inc. (OTC: POTN) today announced that its wholly owned subsidiary, Diamond CBD, Inc., achieved combined sales of more than $3.2 million for July and August. This total is equivalent to 60 percent of the company’s revenues for the first six months of the year, leading PotNetwork to forecast another record-breaking quarter. This projection is further strengthened by Diamond CBD’s early reports for September sales, which the company notes “exceeded expectations” in spite of service interruptions stemming from Hurricane Irma. “We continue to be excited by our continued escalating revenues month-after-month,” Maria Gomez, regional vice president of sales for…

TuesdayOct 17, 2017 11:05 am

NetworkNewsBreaks – RJD Green, Inc. (RJDG) Appoints Bryan Porto to Board of Directors

RJD Green, Inc. (OTC: RJDG), a holding company focused on green environmental services, health care technology and services, and manufacturing/distribution of construction and industrial products, this morning announced changes to its board of directors. In addition to accepting the resignation of Rex Washburn from the position of director due to compelling health issues, the company’s board has accepted the nomination of Bryan Porto as its newest board director. Porto brings more than three decades of senior executive experience to the RJD Green team, having previously served as an officer and board director for companies in both the public and private sectors.…

TuesdayOct 17, 2017 10:24 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Announces Acquisition of Profitable Denver-Based Company

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced its acquisition of a 51 percent stake in JAG, a Denver-based group. Through July 2017, the newly-acquired JAG recorded $600,000 in revenue with gross margins of roughly 26 percent. These results followed full-year 2016 revenue of $700,000 and continued to build on the company’s trend of consistently achieving year-over-year growth since commencing operations in 2014. “We are very excited for this opportunity as it dramatically increases SinglePoint revenues and profitability,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “We look forward to continuing investing in and growing SinglePoint's…

TuesdayOct 17, 2017 9:59 am

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on INM-405 Development

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced preclinical results in the development of INM-405 for the treatment of pain. Notably, results from the company’s studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects. InMed suggests that this lack of side effects may position cannabinoid-based compounds as more desirable treatment options than existing systemic pain-relief administration. News of these findings follows the company’s recent filing of a provisional patent application in the United States…

TuesdayOct 17, 2017 9:28 am

NetworkNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Paul Lucas as New Board Chair

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Paul Lucas as its new independent chair following founder Ken Clement’s decision to step down from the position. Clement will continue to serve as a member of the company’s board of directors. “Ken’s visionary leadership has given ABcann a great foundation to build upon and we appreciate his years of dedicated service and contributions,” Paul Lucas stated in the news release. “Having him maintain his position on the Board will help the Company maintain continuity of leadership and historical knowledge. I am thrilled to take on the…

MondayOct 16, 2017 11:40 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on October 16, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: RCON 140.70% – News: Inks three-year strategic cooperation agreement with BOW Engineering LBIX 35.68% – News: Posts Q2 2017 financial results ARQL 11.35% – News: Closes $15.7M private placement CLSN 7.35% – News: HEAT study highlighted in Clinical Cancer Research publication ETRM 7.22% – News: Presenting at ObesityWeek 2017 October 29 to November 2 SVON 6.34% – News: Receives new European patent covering ELX-02 SNYR 4.35% – News: Names new chief financial officer UTSI 4.28%…

MondayOct 16, 2017 11:37 am

NetworkNewsBreaks – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Receives Reiterated “Buy” Rating at Mizuho Securities

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock following the FDA's Dermatologic and Ophthalmic Drug Advisory Committee vote in favor of Rhopressa. The committee’s decision regarded two key points: efficacy for reducing intraocular pressures (IOP) and efficacy outweighing safety risks. First, the committee voted 10-0 when asked if the clinical trials support Rhopressa's efficacy for reducing elevated IOP for patients with open-angle glaucoma or ocular hypertension. The second question posed to the committee asked if the identified safety risks were outweighed by the efficacy demonstrated…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks